• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Inozyme Pharma Inc (NQ: INZY )

    5.155 +0.095 (+1.88%)
    Streaming Delayed Price Updated: 9:46 AM EDT, Jul 12, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Inozyme Pharma Inc

    < Previous 1 2 Next >
    Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
    Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency 
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
    Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented 
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
    - Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion - 
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Participate in Upcoming Investor Conferences
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
    Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) 
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.